Sadaveri Kirutham (Internal) and Kudasappalaipattai ennai (External) for Atopic dermatitis

Phase II Non-Randomized clinical study on BalaKarappan (Atopic dermatitis) in children with the evaluation of Siddha trial drug Sadaveri kirutham (Internal) and Kudasappalai patai ennai (External) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086698

Enrollment

Registered

2025-05-09

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified Health Condition 2: L209- Atopic dermatitis, unspecified Health Condition 3: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: Sadaveri kirutham (Internal) and Kudasappalaipattai ennai (External): Sadavei kirutham 4ml once a day for 21 days and Kudasappalaipattai ennai application on affected area for 21days In

Eligibility

Inclusion criteria

Inclusion criteria: 1.Intense itching 2.Erythema 3.Papules 4.Papulovesicles 5.Crusted lesion all over the body 6.Ulceration 7.Exudation 8.Constipation

Exclusion criteria

Exclusion criteria: 1.Children above 12 years 2.Scabies 3.Psoriasis 4.Secondary bacterial infection 5.Itchyosis vulgaris 6.Photodermatitis

Design outcomes

Primary

Measure	Time frame
It is mainly assessed by reduction in clinical symptoms (like Intense itching, Papules, Erythema, Papulovesicles, Exudation, Constipation, Ulceration) Comparison with POEM and SCORAD ScaleTimepoint: 21days	—

Secondary

Measure	Time frame
It is assessed by comparing the safety Parameters before and after treatment.Timepoint: 21 days	—

Countries

India

Contacts

Public ContactDr G Srinivasan

Government Siddha Medical college and Hospital, Arumbakkam, Chennai

cspriya2004@gmail.com9445661808

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026